Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is
initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
